Medical Condition News

RSS

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

U.S. cancer rates continue to decline in racial and ethnic populations

Good news in the fight against cancer! A new report from leading health and cancer organizations shows national cancer rates continue to decline.

8 Dec 2009

Animal study demonstrates how whole chromosome changes cause cancer

Mayo Clinic researchers have proven the longstanding theory that changes in the number of whole chromosomes -- called aneuploidy -- can cause cancer by eliminating tumor suppressor genes.

8 Dec 2009

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

BMI and waist circumference explain one half of all fatal and one quarter of all non-fatal cardiovascular disease in those overweight and obese in ten-year follow-up study

8 Dec 2009

Findings shed light on the genetic origins of diabetes

Pediatric researchers have found that a gene already implicated in the development of type 2 diabetes in adults also raises the risk of being overweight during childhood. The finding sheds light on the genetic origins of diabetes and may present an avenue for developing drugs to counteract the disease, which has been on the upswing in childhood and adolescence.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Young adults with higher blood lead levels appear more likely to have major depression and panic disorders, even if they have exposure to lead levels generally considered safe, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Selenium-based antioxidant compound reduces risk of colorectal cancer

Supplementation with a selenium-based antioxidant compound decreased the risk of developing new polyps of the large bowel — called colorectal metachronous adenomas — in people who previously had colorectal polyps removed.

8 Dec 2009

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

New research finding sheds light on the genetic origins of diabetes

8 Dec 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.

8 Dec 2009

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Individuals taking antidepressants may experience personality change, says new report

Individuals taking a medication to treat depression may experience changes in their personality separate from the alleviation of depressive symptoms, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Antiepileptic drugs may have a possible protective effect against seizure disorders

Despite government warnings about an increased risk of suicidal thoughts and actions while taking antiepileptic drugs, these medications do not appear to be associated with increased risk of suicide attempts in individuals with bipolar disorder, and may have a possible protective effect, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

iRGD peptide found to enhance both cancer detection and treatment

Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal tissues.

8 Dec 2009

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

8 Dec 2009

Study suggests sustained health risks linked to adverse childhood experiences

Research from the Institute of Psychiatry at King's College London has found that negative experiences in childhood may alter not only mental health but also physical health, into middle age and beyond.

8 Dec 2009

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Medical Condition News

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

U.S. cancer rates continue to decline in racial and ethnic populations

Animal study demonstrates how whole chromosome changes cause cancer

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

Findings shed light on the genetic origins of diabetes

Amgen announces results from first Phase 1/2 study of Nplate

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Selenium-based antioxidant compound reduces risk of colorectal cancer

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

CAM314 randomized Phase 3 clinical trial results released

New research finding sheds light on the genetic origins of diabetes

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Individuals taking antidepressants may experience personality change, says new report

Antiepileptic drugs may have a possible protective effect against seizure disorders

Social isolation and stress can raise breast cancer risk

iRGD peptide found to enhance both cancer detection and treatment

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Study suggests sustained health risks linked to adverse childhood experiences

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News